Altimmune Highlights Pemvidutide at Major Diabetes Conference
Altimmune Showcases Pemvidutide at Scientific Sessions
GAITHERSBURG, Md. – Altimmune, Inc. (NASDAQ: ALT), a pioneering biopharmaceutical company focused on innovative peptide-based therapies for liver and cardiometabolic diseases, is gearing up for an important event. They will present new findings on pemvidutide at the highly anticipated American Diabetes Association's (ADA) Scientific Sessions.
Details of the Presentations
The company will deliver a compelling oral presentation alongside three poster presentations focusing on pemvidutide, an investigational dual receptor agonist designed to address various metabolic disorders, including metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
Key Oral Presentation
During the conference, Altimmune will hold an oral presentation titled "Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials Testing Incretin-Based Therapies – Take 1" on June 21. This session aims to explore the significant effects of pemvidutide on cardioinflammatory lipids among subjects suffering from obesity.
Poster Presentations
In addition to the oral presentation, Altimmune will display three posters highlighting crucial findings:
- Title: Integrated Analysis Supports Cardiovascular Safety and Risk Reduction with Pemvidutide Treatment (poster #749-P)
- Title: Non-invasive Tests of Central Adiposity Correlate with Reductions in MRI-measured Visceral Adipose Tissue Mass in Subjects with Overweight or Obesity Treated with Pemvidutide (poster #748-P)
- Title: Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Enhances Reverse Cholesterol Transport in a Golden Syrian Hamster Model (poster #778-P)
Each of these presentations will provide insights into how pemvidutide works and the potential it holds for treating conditions linked to obesity and metabolic complications.
About Pemvidutide
Pemvidutide stands out as a novel peptide-based therapy which operates as a dual receptor agonist targeting both GLP-1 and glucagon receptors. Its development is aimed at addressing issues such as MASH, obesity, and alcohol-related disorders. By mimicking the combined beneficial effects of diet and exercise, pemvidutide promotes weight reduction and improves metabolic health, showing promise in clinical trials.
Company Overview: Altimmune, Inc.
With a strong commitment to developing innovative therapies, Altimmune is at the forefront of tackling liver and cardiometabolic diseases. Their lead candidate, pemvidutide, has been recognized for its potential to transform treatment methodologies for obesity and liver diseases.
As the landscape of health care continues evolving, Altimmune remains dedicated to contributing significantly through advancements in biotechnology. Their ongoing trials and presentations at key conferences underline their leadership in the field.
Frequently Asked Questions
What is pemvidutide?
Pemvidutide is an investigational dual receptor agonist designed for treating metabolic disorders, including obesity and liver diseases.
When will the presentations occur?
The oral presentation is scheduled for June 21, with three poster presentations occurring on June 22 at the ADA Scientific Sessions.
Who will present the findings?
Key presentations will be made by leading professionals in the company, including Dr. John J. Suschak and Dr. Shaheen Tomah.
What challenges does pemvidutide aim to address?
Pemvidutide targets issues related to metabolic dysfunction, obesity, and associated liver conditions.
Where can I find more information about Altimmune?
You can visit Altimmune's official website for additional information on their research and development efforts.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.